Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 28, 2018
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
February 27, 2018
HTG Announces New Australian Patent for Its Technology
TUCSON, Ariz., Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today ...
February 27, 2018
Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders
SAN DIEGO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced that, based on the preliminary vote ...
February 27, 2018
Basilea reports significantly improved financial results in 2017
Basel, Switzerland, February 27, 2018 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today its financial results for the financial year 2017 with total revenue increased to ...
February 27, 2018
OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
NANTES, France, Feb. 27, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), today announces that the first approvals to resume patient accrual in the global Tedopi® ...
February 27, 2018
Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor ...
February 27, 2018
ADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
February 27, 2018
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study
VANCOUVER , Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response ...
February 27, 2018
Sierra Oncology Significantly Expands Clinical Development Program
VANCOUVER , Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response ...
February 27, 2018
Sierra Oncology Reports 2017 Year End Results
VANCOUVER, Feb. 27, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
February 27, 2018
Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6
EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
February 27, 2018
CorMedix Inc. Provides Update on Its Financing Plans in Connection with Its Ongoing LOCK-IT 100 Clinical Study
BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 27, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
February 26, 2018
GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study
SAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (LJPC) today announced that an abstract, entitled “Effect of Disease Severity on Survival ...
February 26, 2018
BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Gary ...
February 26, 2018
UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study
DURHAM, NC / ACCESSWIRE / February 26, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system ...
February 26, 2018
CytoSorbents to Participate at the BTIG Healthcare Conference
MONMOUTH JUNCTION, N.J., Feb. 26, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and ...
February 26, 2018
Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679d
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
February 26, 2018
CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma
BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 26, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
February 26, 2018
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)
CUPERTINO, Calif., Feb. 26, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in ...
February 26, 2018
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School to Advance AAV Gene Therapies
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology ...
Page 63 of 117